HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biomarker-based treatment selection in early-stage rectal cancer to promote organ preservation.

AbstractBACKGROUND:
Total mesorectal excision (TME) remains commonplace for T1-2 rectal cancer owing to fear of undertreating a small proportion of patients with node-positive disease. Molecular stratification may predict cancer progression. It could be used to select patients for organ-preserving surgery if specific biomarkers were validated.
METHODS:
Gene methylation was quantified using bisulphite pyrosequencing in 133 unirradiated rectal cancer TME specimens. KRAS mutation and microsatellite instability status were also defined. Molecular parameters were correlated with histopathological indices of disease progression. Predictive models for nodal metastasis, lymphovascular invasion (LVI) and distant metastasis were constructed using a multilevel reverse logistic regression model.
RESULTS:
Methylation of the retinoic acid receptor β gene, RARB, and that of the checkpoint with forkhead and ring finger gene, CHFR, was associated with tumour stage (RARB: 51·9 per cent for T1-2 versus 33·9 per cent for T3-4, P < 0·001; CHFR: 5·5 per cent for T1-2 versus 12·6 per cent for T3-4, P = 0·005). Gene methylation associated with nodal metastasis included RARB (47·1 per cent for N- versus 31·7 per cent for N+; P = 0·008), chemokine ligand 12, CXCL12 (12·3 per cent for N- versus 8·9 per cent for N+; P = 0·021), and death-associated protein kinase 1, DAPK1 (19·3 per cent for N- versus 12·3 per cent for N+; P = 0·022). RARB methylation was also associated with LVI (45·1 per cent for LVI- versus 31·7 per cent for LVI+; P = 0·038). Predictive models for nodal metastasis and LVI achieved sensitivities of 91·1 and 85·0 per cent, and specificities of 55·3 and 45·3 per cent, respectively.
CONCLUSION:
This methylation biomarker panel provides a step towards accurate discrimination of indolent and aggressive rectal cancer subtypes. This could offer an improvement over the current standard of care, whereby fit patients are offered radical surgery.
AuthorsK J Leong, A Beggs, J James, D G Morton, G M Matthews, S P Bach
JournalThe British journal of surgery (Br J Surg) Vol. 101 Issue 10 Pg. 1299-309 (Sep 2014) ISSN: 1365-2168 [Electronic] England
PMID25052224 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
Chemical References
  • Biomarkers, Tumor
  • CXCL12 protein, human
  • Cadherins
  • Cell Cycle Proteins
  • Chemokine CXCL12
  • H-cadherin
  • KRAS protein, human
  • Neoplasm Proteins
  • Poly-ADP-Ribose Binding Proteins
  • Proto-Oncogene Proteins
  • Receptors, Retinoic Acid
  • retinoic acid receptor beta
  • CHFR protein, human
  • Ubiquitin-Protein Ligases
  • DAPK1 protein, human
  • Death-Associated Protein Kinases
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (genetics)
  • Cadherins (genetics)
  • Cell Cycle Proteins (genetics)
  • Chemokine CXCL12 (genetics)
  • DNA Methylation (genetics)
  • Death-Associated Protein Kinases (genetics)
  • Female
  • Humans
  • Lymphatic Metastasis
  • Male
  • Microsatellite Instability
  • Middle Aged
  • Mutation (genetics)
  • Neoplasm Metastasis
  • Neoplasm Proteins (genetics)
  • Organ Sparing Treatments (methods)
  • Patient Selection
  • Poly-ADP-Ribose Binding Proteins
  • Proto-Oncogene Proteins (genetics)
  • Proto-Oncogene Proteins p21(ras)
  • ROC Curve
  • Receptors, Retinoic Acid (genetics)
  • Rectal Neoplasms (genetics, pathology, surgery)
  • Ubiquitin-Protein Ligases
  • ras Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: